Scientists Create “Trojan Horse” Weight Loss Drug That Supercharges Results

Researchers at Helmholtz Munich developed a GLP-1/GIP-based “Trojan horse” drug that carries lanifibranor into target cells.

In obese mice, the hybrid treatment reduced food intake, drove greater weight loss, and improved blood glucose control.

The approach outperformed reference therapies and may boost metabolic effects while limiting whole-body side effects.

The preclinical study suggests a new way to make obesity and type 2 diabetes drugs more effective.